{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:31:13Z","timestamp":1789104673628,"version":"build-2803163510"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001775","name":"University of Technology Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001775","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cancer immunotherapy has transformed the treatment landscape, introducing new strategies to fight various types of cancer. This review examines the important role of vaccines in cancer therapy, focusing on recent advancements such as dendritic cell vaccines, mRNA vaccines, and viral vector-based approaches. The relationship between cancer and the immune system highlights the importance of vaccines as therapeutic tools. The discussion covers tumor cell and dendritic cell vaccines, protein\/peptide vaccines, and nucleic acid vaccines (including DNA, RNA, or viral vector-based), with a focus on their effectiveness and underlying mechanisms. Combination therapies that pair vaccines with immune checkpoint inhibitors, TIL therapy, and TCR\/CAR-T cell therapy show promising potential, boosting antitumor responses. Additionally, the review explores the regulatory functions of microRNAs (miRNAs) in cancer development and suppression, featuring miR-21, miR-155, the let-7 family, and the miR-200 family, among others. These miRNAs influence various pathways, such as PI3K\/AKT, NF-\u03baB, and EMT regulation, providing insights into biomarker-driven therapeutic strategies. Overall, this work offers a thorough overview of vaccines in oncology and the integrative role of miRNAs, setting the stage for the next generation of cancer immunotherapies.<\/jats:p>","DOI":"10.1007\/s00262-025-04011-5","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T17:01:27Z","timestamp":1743699687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A new era of cancer immunotherapy: vaccines and miRNAs"],"prefix":"10.1007","volume":"74","author":[{"given":"Gitika","family":"Sareen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneesh","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashi","family":"Mannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-1590","authenticated-orcid":false,"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"4011_CR1","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3390\/molecules26051315","volume":"26","author":"SA Almatroodi","year":"2021","unstructured":"Almatroodi SA, Alsahli MA, Almatroudi A et al (2021) Potential therapeutic targets of quercetin, a plant flavonol, and its role in the therapy of various types of cancer through the modulation of various cell signaling pathways. Molecules 26:1315. https:\/\/doi.org\/10.3390\/molecules26051315","journal-title":"Molecules"},{"key":"4011_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jcrpr.2017.07.001","volume":"4","author":"SH Hassanpour","year":"2017","unstructured":"Hassanpour SH, Dehghani M (2017) Review of cancer from perspective of molecular. J Cancer Res Pract 4:127\u2013129. https:\/\/doi.org\/10.1016\/j.jcrpr.2017.07.001","journal-title":"J Cancer Res Pract"},{"key":"4011_CR3","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1200\/GO.20.00122","volume":"6","author":"P Mathur","year":"2020","unstructured":"Mathur P, Sathishkumar K, Chaturvedi M et al (2020) Cancer Statistics, 2020: report from national cancer registry programme, India. JCO Glob Oncol 6:1063\u20131075. https:\/\/doi.org\/10.1200\/GO.20.00122","journal-title":"JCO Glob Oncol"},{"key":"4011_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.19.00048","volume":"5","author":"RD Smith","year":"2019","unstructured":"Smith RD, Mallath MK (2019) History of the growing burden of cancer in India: from antiquity to the 21st century. J Glob Oncol 5:1\u201315. https:\/\/doi.org\/10.1200\/JGO.19.00048","journal-title":"J Glob Oncol"},{"key":"4011_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.20892\/j.issn.2095-3941.2022.0231","volume":"19","author":"C Maomao","year":"2022","unstructured":"Maomao C, He L, Dianqin S et al (2022) Current cancer burden in China: epidemiology, etiology, and prevention. Cancer Biol Med 19:1121\u20131138. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2022.0231","journal-title":"Cancer Biol Med"},{"key":"4011_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-57362-1_1","volume":"217","author":"JT Schiller","year":"2021","unstructured":"Schiller JT, Lowy DR (2021) An introduction to virus infections and human cancer. Recent Results Cancer Res 217:1\u201311. https:\/\/doi.org\/10.1007\/978-3-030-57362-1_1","journal-title":"Recent Results Cancer Res"},{"key":"4011_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/carcin\/bgt480","volume":"35","author":"TN Seyfried","year":"2014","unstructured":"Seyfried TN, Flores RE, Poff AM, D\u2019Agostino DP (2014) Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis 35:515\u2013527. https:\/\/doi.org\/10.1093\/carcin\/bgt480","journal-title":"Carcinogenesis"},{"key":"4011_CR8","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/j.jpainsymman.2021.09.011","volume":"63","author":"M Evenepoel","year":"2022","unstructured":"Evenepoel M, Haenen V, De Baerdemaecker T et al (2022) Pain prevalence during cancer treatment: a systematic review and meta-analysis. J Pain Symptom Manage 63:e317\u2013e335. https:\/\/doi.org\/10.1016\/j.jpainsymman.2021.09.011","journal-title":"J Pain Symptom Manage"},{"key":"4011_CR9","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.26355\/eurrev_201806_15270","volume":"22","author":"J-J Wang","year":"2018","unstructured":"Wang J-J, Lei K-F, Han F (2018) Tumor microenvironment: recent advances in various cancer treatments. Eur Rev Med Pharmacol Sci 22:3855\u20133864. https:\/\/doi.org\/10.26355\/eurrev_201806_15270","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"4011_CR10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/978-3-030-12457-1_30","volume":"1131","author":"AM Sterea","year":"2020","unstructured":"Sterea AM, El Hiani Y (2020) The role of mitochondrial calcium signaling in the pathophysiology of cancer cells. Adv Exp Med Biol 1131:747\u2013770. https:\/\/doi.org\/10.1007\/978-3-030-12457-1_30","journal-title":"Adv Exp Med Biol"},{"key":"4011_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111452","volume":"124","author":"A Mannan","year":"2024","unstructured":"Mannan A, Mohan M, Gulati A et al (2024) Aquaporin proteins: a promising frontier for therapeutic intervention in cerebral ischemic injury. Cell Signal 124:111452. https:\/\/doi.org\/10.1016\/j.cellsig.2024.111452","journal-title":"Cell Signal"},{"key":"4011_CR12","doi-asserted-by":"publisher","first-page":"100579","DOI":"10.1016\/j.obmed.2024.100579","volume":"54","author":"N Garg","year":"2025","unstructured":"Garg N, Mannan A, Mohan M, Singh TG (2025) Therapeutic Efficacy of hydroalcoholic extract of Euphorbia prostrata Aiton in NAD-STZ-induced diabetic nephropathy: a multifaceted intervention targeting oxidative stress and inflammation. Obesity Medicine 54:100579. https:\/\/doi.org\/10.1016\/j.obmed.2024.100579","journal-title":"Obesity Medicine"},{"key":"4011_CR13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/ije\/dyac238","volume":"52","author":"S Byrne","year":"2023","unstructured":"Byrne S, Boyle T, Ahmed M et al (2023) Lifestyle, genetic risk and incidence of cancer: a prospective cohort study of 13 cancer types. Int J Epidemiol 52:817\u2013826. https:\/\/doi.org\/10.1093\/ije\/dyac238","journal-title":"Int J Epidemiol"},{"key":"4011_CR14","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1021\/cr900208x","volume":"109","author":"DS Shewach","year":"2009","unstructured":"Shewach DS, Kuchta RD (2009) Introduction to cancer chemotherapeutics. Chem Rev 109:2859\u20132861. https:\/\/doi.org\/10.1021\/cr900208x","journal-title":"Chem Rev"},{"key":"4011_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","volume":"7","author":"D Cardinale","year":"2020","unstructured":"Cardinale D, Iacopo F, Cipolla CM (2020) Cardiotoxicity of anthracyclines. Front Cardiovasc Med 7:26. https:\/\/doi.org\/10.3389\/fcvm.2020.00026","journal-title":"Front Cardiovasc Med"},{"key":"4011_CR16","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ana.24951","volume":"81","author":"NP Staff","year":"2017","unstructured":"Staff NP, Grisold A, Grisold W, Windebank AJ (2017) Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol 81:772\u2013781. https:\/\/doi.org\/10.1002\/ana.24951","journal-title":"Ann Neurol"},{"key":"4011_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/resp.13915","volume":"25","author":"K Long","year":"2020","unstructured":"Long K, Suresh K (2020) Pulmonary toxicity of systemic lung cancer therapy. Respirology 25:72\u201379. https:\/\/doi.org\/10.1111\/resp.13915","journal-title":"Respirology"},{"key":"4011_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.15171\/jnp.2017.41","volume":"6","author":"S Heidari-Soreshjani","year":"2017","unstructured":"Heidari-Soreshjani S, Asadi-Samani M, Yang Q, Saeedi-Boroujeni A (2017) Phytotherapy of nephrotoxicity-induced by cancer drugs: an updated review. J Nephropathol 6:254\u2013263. https:\/\/doi.org\/10.15171\/jnp.2017.41","journal-title":"J Nephropathol"},{"key":"4011_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103660","volume":"173","author":"S Udayakumar","year":"2022","unstructured":"Udayakumar S, Parmar A, Leighl NB et al (2022) Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis. Crit Rev Oncol Hematol 173:103660. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103660","journal-title":"Crit Rev Oncol Hematol"},{"key":"4011_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/B978-0-12-407190-2.00007-1","volume":"119","author":"C Guo","year":"2013","unstructured":"Guo C, Manjili MH, Subjeck JR et al (2013) Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res 119:421\u2013475. https:\/\/doi.org\/10.1016\/B978-0-12-407190-2.00007-1","journal-title":"Adv Cancer Res"},{"key":"4011_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3389\/fphar.2018.00245","volume":"9","author":"K Nurgali","year":"2018","unstructured":"Nurgali K, Jagoe RT, Abalo R (2018) Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front Pharmacol 9:245. https:\/\/doi.org\/10.3389\/fphar.2018.00245","journal-title":"Front Pharmacol"},{"key":"4011_CR22","doi-asserted-by":"publisher","first-page":"668464","DOI":"10.3389\/fonc.2021.668464","volume":"11","author":"AM Grimaldi","year":"2021","unstructured":"Grimaldi AM, Salvatore M, Incoronato M (2021) miRNA-Based therapeutics in breast cancer: a systematic review. Front Oncol 11:668464. https:\/\/doi.org\/10.3389\/fonc.2021.668464","journal-title":"Front Oncol"},{"key":"4011_CR23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga AJ, Chow MT, Luster AD (2021) Chemokines and the immune response to cancer. Immunity 54:859\u2013874. https:\/\/doi.org\/10.1016\/j.immuni.2021.01.012","journal-title":"Immunity"},{"key":"4011_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W et al (2021) Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer 20:131. https:\/\/doi.org\/10.1186\/s12943-021-01428-1","journal-title":"Mol Cancer"},{"key":"4011_CR25","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s11064-023-03873-4","volume":"48","author":"VK Sharma","year":"2023","unstructured":"Sharma VK, Singh TG, Mehta V, Mannan A (2023) Biomarkers: role and scope in neurological disorders. Neurochem Res 48:2029\u20132058. https:\/\/doi.org\/10.1007\/s11064-023-03873-4","journal-title":"Neurochem Res"},{"key":"4011_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","volume":"20","author":"L Xia","year":"2021","unstructured":"Xia L, Oyang L, Lin J et al (2021) The cancer metabolic reprogramming and immune response. Mol Cancer 20:28. https:\/\/doi.org\/10.1186\/s12943-021-01316-8","journal-title":"Mol Cancer"},{"key":"4011_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13201","volume":"96","author":"G Chitadze","year":"2022","unstructured":"Chitadze G, Kabelitz D (2022) Immune surveillance in glioblastoma: Role of the NKG2D system and novel cell-based therapeutic approaches. Scand J Immunol 96:e13201. https:\/\/doi.org\/10.1111\/sji.13201","journal-title":"Scand J Immunol"},{"key":"4011_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002591","volume":"9","author":"S Koyama","year":"2021","unstructured":"Koyama S, Nishikawa H (2021) Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Cancer 9:e002591. https:\/\/doi.org\/10.1136\/jitc-2021-002591","journal-title":"J Immunother Cancer"},{"key":"4011_CR29","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s43440-023-00505-0","volume":"75","author":"M Mohan","year":"2023","unstructured":"Mohan M, Mannan A, Singh TG (2023) Therapeutic implication of Sonic Hedgehog as a potential modulator in ischemic injury. Pharmacol Rep 75:838\u2013860. https:\/\/doi.org\/10.1007\/s43440-023-00505-0","journal-title":"Pharmacol Rep"},{"key":"4011_CR30","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.3390\/ijms20184413","volume":"20","author":"SM Ferrari","year":"2019","unstructured":"Ferrari SM, Fallahi P, Galdiero MR et al (2019) Immune and inflammatory cells in thyroid cancer microenvironment. Int J Mol Sci 20:4413. https:\/\/doi.org\/10.3390\/ijms20184413","journal-title":"Int J Mol Sci"},{"key":"4011_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s12276-021-00612-z","volume":"53","author":"A Berglund","year":"2021","unstructured":"Berglund A, Putney RM, Hamaidi I, Kim S (2021) Epigenetic dysregulation of immune-related pathways in cancer: bioinformatics tools and visualization. Exp Mol Med 53:761\u2013771. https:\/\/doi.org\/10.1038\/s12276-021-00612-z","journal-title":"Exp Mol Med"},{"key":"4011_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141669","volume":"10","author":"W Deisting","year":"2015","unstructured":"Deisting W, Raum T, Kufer P et al (2015) Impact of diverse immune evasion mechanisms of cancer cells on T cells engaged by EpCAM\/CD3-bispecific antibody construct AMG 110. PLoS ONE 10:e0141669. https:\/\/doi.org\/10.1371\/journal.pone.0141669","journal-title":"PLoS ONE"},{"key":"4011_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2024.115242","volume":"476","author":"M Mohan","year":"2024","unstructured":"Mohan M, Mannan A, Nauriyal A, Singh TG (2024) Emerging targets in amyotrophic lateral sclerosis (ALS): the promise of ATP-binding cassette (ABC) transporter modulation. Behav Brain Res 476:115242. https:\/\/doi.org\/10.1016\/j.bbr.2024.115242","journal-title":"Behav Brain Res"},{"key":"4011_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.809761","volume":"13","author":"Z Liu","year":"2022","unstructured":"Liu Z, Ren Y, Weng S et al (2022) A new trend in cancer treatment: the combination of epigenetics and immunotherapy. Front Immunol 13:809761. https:\/\/doi.org\/10.3389\/fimmu.2022.809761","journal-title":"Front Immunol"},{"key":"4011_CR35","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17:807\u2013821. https:\/\/doi.org\/10.1038\/s41423-020-0488-6","journal-title":"Cell Mol Immunol"},{"key":"4011_CR36","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.it.2020.06.002","volume":"41","author":"L Villanueva","year":"2020","unstructured":"Villanueva L, \u00c1lvarez-Errico D, Esteller M (2020) The contribution of epigenetics to cancer immunotherapy. Trends Immunol 41:676\u2013691. https:\/\/doi.org\/10.1016\/j.it.2020.06.002","journal-title":"Trends Immunol"},{"key":"4011_CR37","doi-asserted-by":"publisher","first-page":"5825401","DOI":"10.1155\/2020\/5825401","volume":"2020","author":"Y Igarashi","year":"2020","unstructured":"Igarashi Y, Sasada T (2020) Cancer vaccines: toward the next breakthrough in cancer immunotherapy. J Immunol Res 2020:5825401. https:\/\/doi.org\/10.1155\/2020\/5825401","journal-title":"J Immunol Res"},{"key":"4011_CR38","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.4161\/21645515.2014.980686","volume":"10","author":"B Yang","year":"2014","unstructured":"Yang B, Jeang J, Yang A et al (2014) DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother 10:3153\u20133164. https:\/\/doi.org\/10.4161\/21645515.2014.980686","journal-title":"Hum Vaccin Immunother"},{"key":"4011_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1559","volume":"11","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Lin S, Wang X-Y, Zhu G (2019) Nanovaccines for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 11:e1559. https:\/\/doi.org\/10.1002\/wnan.1559","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"4011_CR40","doi-asserted-by":"publisher","DOI":"10.2174\/0113894501320839240918110656","author":"M Mohan","year":"2024","unstructured":"Mohan M, Mannan A, Kakkar C, Singh TG (2024) Nrf2 and ferroptosis: exploring translational avenues for therapeutic approaches to neurological diseases. Curr Drug Targets. https:\/\/doi.org\/10.2174\/0113894501320839240918110656","journal-title":"Curr Drug Targets"},{"key":"4011_CR41","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2022.05.015","volume":"40","author":"JT Schiller","year":"2022","unstructured":"Schiller JT, Lowy DR, Frazer IH et al (2022) Cancer vaccines. Cancer Cell 40:559\u2013564. https:\/\/doi.org\/10.1016\/j.ccell.2022.05.015","journal-title":"Cancer Cell"},{"key":"4011_CR42","doi-asserted-by":"publisher","first-page":"20160268","DOI":"10.1098\/rstb.2016.0268","volume":"372","author":"M Stanley","year":"2017","unstructured":"Stanley M (2017) Tumour virus vaccines: hepatitis B virus and human papillomavirus. Philos Trans R Soc Lond B Biol Sci 372:20160268. https:\/\/doi.org\/10.1098\/rstb.2016.0268","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"4011_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102429","volume":"109","author":"N Sobhani","year":"2022","unstructured":"Sobhani N, Scaggiante B, Morris R et al (2022) Therapeutic cancer vaccines: from biological mechanisms and engineering to ongoing clinical trials. Cancer Treat Rev 109:102429. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102429","journal-title":"Cancer Treat Rev"},{"key":"4011_CR44","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.3390\/cancers15061779","volume":"15","author":"A Alsalloum","year":"2023","unstructured":"Alsalloum A, Shevchenko JA, Sennikov S (2023) The melanoma-associated antigen family A (MAGE-A): a promising target for cancer immunotherapy? Cancers 15:1779. https:\/\/doi.org\/10.3390\/cancers15061779","journal-title":"Cancers"},{"key":"4011_CR45","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3390\/vaccines11101599","volume":"11","author":"L Ni","year":"2023","unstructured":"Ni L (2023) Advances in mRNA-Based Cancer Vaccines. Vaccines 11:1599. https:\/\/doi.org\/10.3390\/vaccines11101599","journal-title":"Vaccines"},{"key":"4011_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101481","volume":"52","author":"AE Marciscano","year":"2021","unstructured":"Marciscano AE, Anandasabapathy N (2021) The role of dendritic cells in cancer and anti-tumor immunity. Semin Immunol 52:101481. https:\/\/doi.org\/10.1016\/j.smim.2021.101481","journal-title":"Semin Immunol"},{"key":"4011_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11523-020-00788-w","volume":"16","author":"MA Morse","year":"2021","unstructured":"Morse MA, Gwin WR, Mitchell DA (2021) Vaccine therapies for cancer: then and now. Target Oncol 16:121\u2013152. https:\/\/doi.org\/10.1007\/s11523-020-00788-w","journal-title":"Target Oncol"},{"key":"4011_CR48","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1016\/j.cell.2022.10.006","volume":"185","author":"F Baharom","year":"2022","unstructured":"Baharom F, Ramirez-Valdez RA, Khalilnezhad A et al (2022) Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment. Cell 185:4317-4332.e15. https:\/\/doi.org\/10.1016\/j.cell.2022.10.006","journal-title":"Cell"},{"key":"4011_CR49","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4049\/jimmunol.1701024","volume":"200","author":"PM Santos","year":"2018","unstructured":"Santos PM, Butterfield LH (2018) Dendritic cell-based cancer vaccines. J Immunol 200:443\u2013449. https:\/\/doi.org\/10.4049\/jimmunol.1701024","journal-title":"J Immunol"},{"key":"4011_CR50","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.3390\/cells12172147","volume":"12","author":"K-W Lee","year":"2023","unstructured":"Lee K-W, Yam JWP, Mao X (2023) Dendritic cell vaccines: a shift from conventional approach to new generations. Cells 12:2147. https:\/\/doi.org\/10.3390\/cells12172147","journal-title":"Cells"},{"key":"4011_CR51","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3389\/fimmu.2015.00243","volume":"6","author":"S Mac Keon","year":"2015","unstructured":"Mac Keon S, Ruiz MS, Gazzaniga S, Wainstok R (2015) dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol 6:243. https:\/\/doi.org\/10.3389\/fimmu.2015.00243","journal-title":"Front Immunol"},{"key":"4011_CR52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/(sici)1096-9098(199806)68:2<79::aid-jso3>3.0.co;2-h","volume":"68","author":"P DeMatos","year":"1998","unstructured":"DeMatos P, Abdel-Wahab Z, Vervaert C et al (1998) Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J Surg Oncol 68:79\u201391. https:\/\/doi.org\/10.1002\/(sici)1096-9098(199806)68:2%3c79::aid-jso3%3e3.0.co;2-h","journal-title":"J Surg Oncol"},{"key":"4011_CR53","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s12276-023-01016-x","volume":"55","author":"SMP Vadevoo","year":"2023","unstructured":"Vadevoo SMP, Gurung S, Lee H-S et al (2023) Peptides as multifunctional players in cancer therapy. Exp Mol Med 55:1099\u20131109. https:\/\/doi.org\/10.1038\/s12276-023-01016-x","journal-title":"Exp Mol Med"},{"key":"4011_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110721","volume":"123","author":"F Zahedipour","year":"2023","unstructured":"Zahedipour F, Jamialahmadi K, Zamani P, Reza Jaafari M (2023) Improving the efficacy of peptide vaccines in cancer immunotherapy. Int Immunopharmacol 123:110721. https:\/\/doi.org\/10.1016\/j.intimp.2023.110721","journal-title":"Int Immunopharmacol"},{"key":"4011_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202301096","volume":"12","author":"N Falcone","year":"2023","unstructured":"Falcone N, Ermis M, Tamay DG et al (2023) Peptide hydrogels as immunomaterials and their use in cancer immunotherapy delivery. Adv Healthc Mater 12:e2301096. https:\/\/doi.org\/10.1002\/adhm.202301096","journal-title":"Adv Healthc Mater"},{"key":"4011_CR56","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.imlet.2005.09.004","volume":"102","author":"X Qian","year":"2006","unstructured":"Qian X, Lu Y, Liu Q et al (2006) Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta\/mE7\/TBhsp70Delta fusion protein vaccine in an animal model. Immunol Lett 102:191\u2013201. https:\/\/doi.org\/10.1016\/j.imlet.2005.09.004","journal-title":"Immunol Lett"},{"key":"4011_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.633776","volume":"9","author":"F Qin","year":"2021","unstructured":"Qin F, Xia F, Chen H et al (2021) A guide to nucleic acid vaccines in the prevention and treatment of infectious diseases and cancers: from basic principles to current applications. Front Cell Dev Biol 9:633776. https:\/\/doi.org\/10.3389\/fcell.2021.633776","journal-title":"Front Cell Dev Biol"},{"key":"4011_CR58","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.drudis.2019.12.003","volume":"25","author":"Z Jahanafrooz","year":"2020","unstructured":"Jahanafrooz Z, Baradaran B, Mosafer J et al (2020) Comparison of DNA and mRNA vaccines against cancer. Drug Discov Today 25:552\u2013560. https:\/\/doi.org\/10.1016\/j.drudis.2019.12.003","journal-title":"Drug Discov Today"},{"key":"4011_CR59","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu J, Fu M, Wang M et al (2022) Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol 15:28. https:\/\/doi.org\/10.1186\/s13045-022-01247-x","journal-title":"J Hematol Oncol"},{"key":"4011_CR60","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1586\/14760584.2016.1124762","volume":"15","author":"L Li","year":"2016","unstructured":"Li L, Petrovsky N (2016) Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines 15:313\u2013329. https:\/\/doi.org\/10.1586\/14760584.2016.1124762","journal-title":"Expert Rev Vaccines"},{"key":"4011_CR61","doi-asserted-by":"publisher","first-page":"1389971","DOI":"10.3389\/fimmu.2024.1389971","volume":"15","author":"BP Satapathy","year":"2024","unstructured":"Satapathy BP, Sheoran P, Yadav R et al (2024) The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review. Front Immunol 15:1389971. https:\/\/doi.org\/10.3389\/fimmu.2024.1389971","journal-title":"Front Immunol"},{"key":"4011_CR62","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ymthe.2023.10.024","volume":"32","author":"R Malla","year":"2024","unstructured":"Malla R, Srilatha M, Farran B, Nagaraju GP (2024) mRNA vaccines and their delivery strategies: a journey from infectious diseases to cancer. Mol Ther 32:13\u201331. https:\/\/doi.org\/10.1016\/j.ymthe.2023.10.024","journal-title":"Mol Ther"},{"key":"4011_CR63","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/PPO.0b013e3182325e63","volume":"17","author":"C Larocca","year":"2011","unstructured":"Larocca C, Schlom J (2011) Viral vector-based therapeutic cancer vaccines. Cancer J 17:359\u2013371. https:\/\/doi.org\/10.1097\/PPO.0b013e3182325e63","journal-title":"Cancer J"},{"key":"4011_CR64","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41541-023-00671-5","volume":"8","author":"N Viborg","year":"2023","unstructured":"Viborg N, Pavlidis MA, Barrio-Calvo M et al (2023) DNA based neoepitope vaccination induces tumor control in syngeneic mouse models. NPJ Vaccines 8:77. https:\/\/doi.org\/10.1038\/s41541-023-00671-5","journal-title":"NPJ Vaccines"},{"key":"4011_CR65","doi-asserted-by":"publisher","first-page":"2202127","DOI":"10.1080\/21645515.2023.2202127","volume":"19","author":"Y Wang","year":"2023","unstructured":"Wang Y, Song W, Xu Q et al (2023) Adjuvant DNA vaccine pNMM promotes enhanced specific immunity and anti-tumor effects. Hum Vaccin Immunother 19:2202127. https:\/\/doi.org\/10.1080\/21645515.2023.2202127","journal-title":"Hum Vaccin Immunother"},{"key":"4011_CR66","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1007\/s00018-004-4255-0","volume":"61","author":"J-P Carralot","year":"2004","unstructured":"Carralot J-P, Probst J, Hoerr I et al (2004) Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci 61:2418\u20132424. https:\/\/doi.org\/10.1007\/s00018-004-4255-0","journal-title":"Cell Mol Life Sci"},{"key":"4011_CR67","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ajps.2022.05.003","volume":"17","author":"M Karam","year":"2022","unstructured":"Karam M, Daoud G (2022) mRNA vaccines: past, present, future. Asian J Pharm Sci 17:491\u2013522. https:\/\/doi.org\/10.1016\/j.ajps.2022.05.003","journal-title":"Asian J Pharm Sci"},{"key":"4011_CR68","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1479-0556-7-2","volume":"7","author":"M-D Lai","year":"2009","unstructured":"Lai M-D, Yen M-C, Lin C-M et al (2009) The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model. Genet Vaccines Ther 7:2. https:\/\/doi.org\/10.1186\/1479-0556-7-2","journal-title":"Genet Vaccines Ther"},{"key":"4011_CR69","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.3390\/ph16101384","volume":"16","author":"D Liu","year":"2023","unstructured":"Liu D, Che X, Wang X et al (2023) Tumor vaccines: unleashing the power of the immune system to fight cancer. Pharmaceuticals 16:1384. https:\/\/doi.org\/10.3390\/ph16101384","journal-title":"Pharmaceuticals"},{"key":"4011_CR70","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1095433","volume":"5","author":"L-S Chang","year":"2015","unstructured":"Chang L-S, Yan W-L, Chang Y-W et al (2015) Gemcitabine enhances antitumor efficacy of recombinant lipoimmunogen-based immunotherapy. Oncoimmunology 5:e1095433. https:\/\/doi.org\/10.1080\/2162402X.2015.1095433","journal-title":"Oncoimmunology"},{"key":"4011_CR71","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12:237. https:\/\/doi.org\/10.1038\/nrc3237","journal-title":"Nat Rev Cancer"},{"key":"4011_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577869","volume":"11","author":"C Yang","year":"2020","unstructured":"Yang C, Xia B-R, Zhang Z-C et al (2020) Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Front Immunol 11:577869. https:\/\/doi.org\/10.3389\/fimmu.2020.577869","journal-title":"Front Immunol"},{"key":"4011_CR73","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.colsurfb.2016.03.075","volume":"143","author":"E Muntimadugu","year":"2016","unstructured":"Muntimadugu E, Kumar R, Saladi S et al (2016) CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel. Colloids Surf, B 143:532\u2013546. https:\/\/doi.org\/10.1016\/j.colsurfb.2016.03.075","journal-title":"Colloids Surf, B"},{"key":"4011_CR74","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.3390\/cancers14205160","volume":"14","author":"N Wang","year":"2022","unstructured":"Wang N, Cao Y, Si C et al (2022) Emerging role of ERBB2 in targeted therapy for metastatic colorectal cancer: signaling pathways to therapeutic strategies. Cancers 14:5160. https:\/\/doi.org\/10.3390\/cancers14205160","journal-title":"Cancers"},{"key":"4011_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5487\/TR.2014.30.1.001","volume":"30","author":"J Jung","year":"2014","unstructured":"Jung J (2014) Human tumor xenograft models for preclinical assessment of anticancer drug development. Toxicol Res 30:1\u20135. https:\/\/doi.org\/10.5487\/TR.2014.30.1.001","journal-title":"Toxicol Res"},{"key":"4011_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188740","volume":"12","author":"A Denslow","year":"2017","unstructured":"Denslow A, \u015awitalska M, Jarosz J et al (2017) Clopidogrel in a combined therapy with anticancer drugs\u2014effect on tumor growth, metastasis, and treatment toxicity: studies in animal models. PLoS ONE 12:e0188740. https:\/\/doi.org\/10.1371\/journal.pone.0188740","journal-title":"PLoS ONE"},{"key":"4011_CR77","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1089\/pho.2017.4291","volume":"35","author":"J Lee","year":"2017","unstructured":"Lee J, Park HY, Kim WW et al (2017) Combination treatment with photodynamic therapy and laser ablation in breast cancer: an animal model study. Photomed Laser Surg 35:505\u2013512. https:\/\/doi.org\/10.1089\/pho.2017.4291","journal-title":"Photomed Laser Surg"},{"key":"4011_CR78","doi-asserted-by":"publisher","first-page":"8035","DOI":"10.3390\/ijms22158035","volume":"22","author":"C-G Kim","year":"2021","unstructured":"Kim C-G, Sang Y-B, Lee J-H, Chon H-J (2021) Combining cancer vaccines with immunotherapy: establishing a new immunological approach. Int J Mol Sci 22:8035. https:\/\/doi.org\/10.3390\/ijms22158035","journal-title":"Int J Mol Sci"},{"key":"4011_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.905520","volume":"12","author":"L Li","year":"2022","unstructured":"Li L, Wen Q, Ding R (2022) Therapeutic targeting of VEGF and\/or TGF-\u03b2 to enhance anti-PD-(L)1 therapy: the evidence from clinical trials. Front Oncol 12:905520. https:\/\/doi.org\/10.3389\/fonc.2022.905520","journal-title":"Front Oncol"},{"key":"4011_CR80","doi-asserted-by":"publisher","first-page":"5416923","DOI":"10.1155\/2018\/5416923","volume":"2018","author":"LTH Phi","year":"2018","unstructured":"Phi LTH, Sari IN, Yang Y-G et al (2018) Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int 2018:5416923. https:\/\/doi.org\/10.1155\/2018\/5416923","journal-title":"Stem Cells Int"},{"key":"4011_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2023.103648","volume":"43","author":"BK Najafabad","year":"2023","unstructured":"Najafabad BK, Attaran N, Mahmoudi M, Sazgarnia A (2023) Effect of photothermal and photodynamic therapy with cobalt ferrite superparamagnetic nanoparticles loaded with ICG and PpIX on cancer stem cells in MDA-MB-231 and A375 cell lines. Photodiagn Photodyn Ther 43:103648. https:\/\/doi.org\/10.1016\/j.pdpdt.2023.103648","journal-title":"Photodiagn Photodyn Ther"},{"key":"4011_CR82","volume-title":"Medical Genetics Summaries","author":"L Dean","year":"2012","unstructured":"Dean L, Kane M (2012) Clopidogrel Therapy and CYP2C19 Genotype. In: Pratt VM, Scott SA, Pirmohamed M et al (eds) Medical Genetics Summaries. National Center for Biotechnology Information (US), Bethesda"},{"key":"4011_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111095","volume":"125","author":"A Mannan","year":"2023","unstructured":"Mannan A, Kakkar C, Dhiman S, Singh TG (2023) Advancing the frontiers of adaptive cell therapy: a transformative mechanistic journey from preclinical to clinical settings. Int Immunopharmacol 125:111095. https:\/\/doi.org\/10.1016\/j.intimp.2023.111095","journal-title":"Int Immunopharmacol"},{"issue":"21","key":"4011_CR84","doi-asserted-by":"publisher","first-page":"00004","DOI":"10.1016\/j.drudis.2021.01.002","volume":"S1359\u20136446","author":"S Kumar","year":"2021","unstructured":"Kumar S, Singh SK, Rana B, Rana A (2021) Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights. Drug Discov Today S1359\u20136446(21):00004. https:\/\/doi.org\/10.1016\/j.drudis.2021.01.002","journal-title":"Drug Discov Today"},{"key":"4011_CR85","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40425-015-0056-2","volume":"3","author":"MD Roth","year":"2015","unstructured":"Roth MD, Harui A (2015) Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model. J Immunother Cancer 3:12. https:\/\/doi.org\/10.1186\/s40425-015-0056-2","journal-title":"J Immunother Cancer"},{"key":"4011_CR86","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.3390\/cancers12071920","volume":"12","author":"A Morales-Molina","year":"2020","unstructured":"Morales-Molina A, Rodr\u00edguez-Milla M\u00c1, Gimenez-Sanchez A et al (2020) Cellular virotherapy increases tumor-infiltrating lymphocytes (TIL) and decreases their PD-1+ subsets in mouse immunocompetent models. Cancers 12:1920. https:\/\/doi.org\/10.3390\/cancers12071920","journal-title":"Cancers"},{"key":"4011_CR87","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.apsb.2020.10.020","volume":"11","author":"H Dana","year":"2021","unstructured":"Dana H, Chalbatani GM, Jalali SA et al (2021) CAR-T cells: early successes in blood cancer and challenges in solid tumors. Acta Pharm Sin B 11:1129\u20131147. https:\/\/doi.org\/10.1016\/j.apsb.2020.10.020","journal-title":"Acta Pharm Sin B"},{"key":"4011_CR88","doi-asserted-by":"publisher","first-page":"12317","DOI":"10.3390\/ijms241512317","volume":"24","author":"W Wei","year":"2023","unstructured":"Wei W, Chen Z-N, Wang K (2023) CRISPR\/Cas9: a powerful strategy to improve CAR-T cell persistence. Int J Mol Sci 24:12317. https:\/\/doi.org\/10.3390\/ijms241512317","journal-title":"Int J Mol Sci"},{"key":"4011_CR89","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","volume":"31","author":"T Gaj","year":"2013","unstructured":"Gaj T, Gersbach CA, Barbas CF (2013) ZFN, TALEN and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol 31:397\u2013405. https:\/\/doi.org\/10.1016\/j.tibtech.2013.04.004","journal-title":"Trends Biotechnol"},{"key":"4011_CR90","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13046-021-02076-5","volume":"40","author":"S Ghaffari","year":"2021","unstructured":"Ghaffari S, Khalili N, Rezaei N (2021) CRISPR\/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy. J Exp Clin Cancer Res 40:269. https:\/\/doi.org\/10.1186\/s13046-021-02076-5","journal-title":"J Exp Clin Cancer Res"},{"key":"4011_CR91","doi-asserted-by":"publisher","first-page":"105266","DOI":"10.1016\/j.ebiom.2024.105266","volume":"106","author":"TA Bui","year":"2024","unstructured":"Bui TA, Mei H, Sang R et al (2024) Advancements and challenges in developing in\u00a0vivo CAR T cell therapies for cancer treatment. eBioMedicine 106:105266. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105266","journal-title":"eBioMedicine"},{"key":"4011_CR92","doi-asserted-by":"publisher","first-page":"1011858","DOI":"10.3389\/fimmu.2022.1011858","volume":"13","author":"N Maldonado-P\u00e9rez","year":"2022","unstructured":"Maldonado-P\u00e9rez N, Trist\u00e1n-Manzano M, Justicia-Lirio P et al (2022) Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma. Front Immunol 13:1011858. https:\/\/doi.org\/10.3389\/fimmu.2022.1011858","journal-title":"Front Immunol"},{"key":"4011_CR93","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"4011_CR94","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L (2020) PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10:727\u2013742","journal-title":"Am J Cancer Res"},{"key":"4011_CR95","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R et al (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:561. https:\/\/doi.org\/10.3389\/fphar.2017.00561","journal-title":"Front Pharmacol"},{"key":"4011_CR96","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA et al (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29:3044\u20133060. https:\/\/doi.org\/10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"4011_CR97","doi-asserted-by":"publisher","first-page":"1296341","DOI":"10.3389\/fimmu.2023.1296341","volume":"14","author":"A Parvez","year":"2023","unstructured":"Parvez A, Choudhary F, Mudgal P et al (2023) PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Front Immunol 14:1296341. https:\/\/doi.org\/10.3389\/fimmu.2023.1296341","journal-title":"Front Immunol"},{"key":"4011_CR98","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2967\/jnumed.120.246041","volume":"62","author":"J Czernin","year":"2021","unstructured":"Czernin J, Current K, Mona CE et al (2021) Immune-checkpoint blockade enhances 225Ac-PSMA617 efficacy in a mouse model of prostate cancer. J Nucl Med 62:228\u2013231. https:\/\/doi.org\/10.2967\/jnumed.120.246041","journal-title":"J Nucl Med"},{"key":"4011_CR99","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.7150\/ijbs.47203","volume":"16","author":"B He","year":"2020","unstructured":"He B, Zhao Z, Cai Q et al (2020) miRNA-based biomarkers, therapies, and resistance in cancer. Int J Biol Sci 16:2628\u20132647. https:\/\/doi.org\/10.7150\/ijbs.47203","journal-title":"Int J Biol Sci"},{"key":"4011_CR100","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1186\/s12885-019-6284-y","volume":"19","author":"AZ Daoud","year":"2019","unstructured":"Daoud AZ, Mulholland EJ, Cole G, McCarthy HO (2019) MicroRNAs in pancreatic cancer: biomarkers, prognostic, and therapeutic modulators. BMC Cancer 19:1130. https:\/\/doi.org\/10.1186\/s12885-019-6284-y","journal-title":"BMC Cancer"},{"key":"4011_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122537","volume":"342","author":"S Dhiman","year":"2024","unstructured":"Dhiman S, Mannan A, Taneja A et al (2024) Sirtuin dysregulation in Parkinson\u2019s disease: implications of acetylation and deacetylation processes. Life Sci 342:122537. https:\/\/doi.org\/10.1016\/j.lfs.2024.122537","journal-title":"Life Sci"},{"key":"4011_CR102","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrc3932","volume":"15","author":"S Lin","year":"2015","unstructured":"Lin S, Gregory RI (2015) MicroRNA biogenesis pathways in cancer. Nat Rev Cancer 15:321\u2013333. https:\/\/doi.org\/10.1038\/nrc3932","journal-title":"Nat Rev Cancer"},{"key":"4011_CR103","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.3390\/cells10082069","volume":"10","author":"I Conti","year":"2021","unstructured":"Conti I, Simioni C, Varano G et al (2021) MicroRNAs patterns as potential tools for diagnostic and prognostic follow-up in cancer survivorship. Cells 10:2069. https:\/\/doi.org\/10.3390\/cells10082069","journal-title":"Cells"},{"key":"4011_CR104","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3390\/ijms21051723","volume":"21","author":"Z Ali Syeda","year":"2020","unstructured":"Ali Syeda Z, Langden SSS, Munkhzul C et al (2020) Regulatory mechanism of MicroRNA expression in cancer. Int J Mol Sci 21:1723. https:\/\/doi.org\/10.3390\/ijms21051723","journal-title":"Int J Mol Sci"},{"key":"4011_CR105","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1097\/CAD.0000000000000555","volume":"28","author":"H Yong-Ming","year":"2017","unstructured":"Yong-Ming H, Ai-Jun J, Xiao-Yue X et al (2017) miR-449a: a potential therapeutic agent for cancer. Anticancer Drugs 28:1067\u20131078. https:\/\/doi.org\/10.1097\/CAD.0000000000000555","journal-title":"Anticancer Drugs"},{"key":"4011_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.913951","volume":"13","author":"K Otmani","year":"2022","unstructured":"Otmani K, Rouas R, Lewalle P (2022) OncomiRs as noncoding RNAs having functions in cancer: their role in immune suppression and clinical implications. Front Immunol 13:913951. https:\/\/doi.org\/10.3389\/fimmu.2022.913951","journal-title":"Front Immunol"},{"key":"4011_CR107","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1631\/jzus.B1400184","volume":"16","author":"W Wang","year":"2015","unstructured":"Wang W, Luo Y (2015) MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential. J Zhejiang Univ Sci B 16:18\u201331. https:\/\/doi.org\/10.1631\/jzus.B1400184","journal-title":"J Zhejiang Univ Sci B"},{"key":"4011_CR108","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/ncb1681","volume":"10","author":"Q Huang","year":"2008","unstructured":"Huang Q, Gumireddy K, Schrier M et al (2008) The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 10:202\u2013210. https:\/\/doi.org\/10.1038\/ncb1681","journal-title":"Nat Cell Biol"},{"key":"4011_CR109","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/135632","volume":"2010","author":"L-H Chen","year":"2010","unstructured":"Chen L-H, Tsai K-L, Chen Y-W et al (2010) MicroRNA as a novel modulator in head and neck squamous carcinoma. J Oncol 2010:135632. https:\/\/doi.org\/10.1155\/2010\/135632","journal-title":"J Oncol"},{"key":"4011_CR110","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1530\/VB-20-0012","volume":"2","author":"D Sawant","year":"2020","unstructured":"Sawant D, Lilly B (2020) MicroRNA-145 targets in cancer and the cardiovascular system: evidence for common signaling pathways. Vasc Biol 2:R115\u2013R128. https:\/\/doi.org\/10.1530\/VB-20-0012","journal-title":"Vasc Biol"},{"key":"4011_CR111","doi-asserted-by":"publisher","first-page":"5874","DOI":"10.3390\/cancers13235874","volume":"13","author":"I Cavallari","year":"2021","unstructured":"Cavallari I, Ciccarese F, Sharova E et al (2021) The miR-200 family of microRNAs: fine tuners of epithelial-mesenchymal transition and circulating cancer biomarkers. Cancers 13:5874. https:\/\/doi.org\/10.3390\/cancers13235874","journal-title":"Cancers"},{"key":"4011_CR112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092099","volume":"9","author":"Y Hu","year":"2014","unstructured":"Hu Y, Zhu Q, Tang L (2014) MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression. PLoS ONE 9:e92099. https:\/\/doi.org\/10.1371\/journal.pone.0092099","journal-title":"PLoS ONE"},{"key":"4011_CR113","first-page":"1782","volume":"26","author":"L Han","year":"2021","unstructured":"Han L (2021) miR-99a inhibits proliferation and migration of cervical cancer cells by targeting IGF1R. J BUON 26:1782\u20131788","journal-title":"J BUON"},{"key":"4011_CR114","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/jcb.24965","volume":"116","author":"S Yu","year":"2015","unstructured":"Yu S, Zhang C, Dong F, Zhang Y (2015) miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway. J Cell Biochem 116:268\u2013276. https:\/\/doi.org\/10.1002\/jcb.24965","journal-title":"J Cell Biochem"},{"key":"4011_CR115","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3892\/ol.2015.2873","volume":"9","author":"C Chen","year":"2015","unstructured":"Chen C, Zhao Z, Liu Y, Mu Y (2015) microRNA-99a is downregulated and promotes proliferation, migration and invasion in non-small cell lung cancer A549 and H1299 cells. Oncol Lett 9:1128\u20131134. https:\/\/doi.org\/10.3892\/ol.2015.2873","journal-title":"Oncol Lett"},{"key":"4011_CR116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031032","volume":"7","author":"G Turcatel","year":"2012","unstructured":"Turcatel G, Rubin N, El-Hashash A, Warburton D (2012) MIR-99a and MIR-99b modulate TGF-\u03b2 induced epithelial to mesenchymal plasticity in normal murine mammary gland cells. PLoS ONE 7:e31032. https:\/\/doi.org\/10.1371\/journal.pone.0031032","journal-title":"PLoS ONE"},{"key":"4011_CR117","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3390\/medicina60030486","volume":"60","author":"I Iavarone","year":"2024","unstructured":"Iavarone I, Molitierno R, Fumiento P et al (2024) MicroRNA expression in endometrial cancer: current knowledge and therapeutic implications. Medicina 60:486. https:\/\/doi.org\/10.3390\/medicina60030486","journal-title":"Medicina"},{"key":"4011_CR118","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY et al (2023) PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 22:138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6","journal-title":"Mol Cancer"},{"key":"4011_CR119","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.3390\/ijms24031980","volume":"24","author":"EA Sidorova","year":"2023","unstructured":"Sidorova EA, Zhernov YV, Antsupova MA et al (2023) The role of different types of microRNA in the pathogenesis of breast and prostate cancer. Int J Mol Sci 24:1980. https:\/\/doi.org\/10.3390\/ijms24031980","journal-title":"Int J Mol Sci"},{"key":"4011_CR120","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.7150\/jca.84030","volume":"14","author":"P Gao","year":"2023","unstructured":"Gao P, Wang H, Li H et al (2023) miR-21-5p inhibits the proliferation, migration, and invasion of glioma by targeting S100A10. J Cancer 14:1781\u20131793. https:\/\/doi.org\/10.7150\/jca.84030","journal-title":"J Cancer"},{"key":"4011_CR121","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11033-024-09352-5","volume":"51","author":"S Babadag","year":"2024","unstructured":"Babadag S, Altundag-Erdogan \u00d6, Akkaya-Ulum YZ, \u00c7elebi-Saltik B (2024) The role of telocytes and miR-21-5p in tumorigenicity and metastasis of breast cancer stem cells. Mol Biol Rep 51:395. https:\/\/doi.org\/10.1007\/s11033-024-09352-5","journal-title":"Mol Biol Rep"},{"key":"4011_CR122","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1016\/j.jid.2020.03.949","volume":"140","author":"E Dika","year":"2020","unstructured":"Dika E, Riefolo M, Porcellini E et al (2020) Defining the prognostic role of microRNAs in cutaneous melanoma. J Invest Dermatol 140:2260\u20132267. https:\/\/doi.org\/10.1016\/j.jid.2020.03.949","journal-title":"J Invest Dermatol"},{"key":"4011_CR123","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41419-018-0928-8","volume":"9","author":"Q Li","year":"2018","unstructured":"Li Q, Li B, Li Q et al (2018) Exosomal miR-21-5p derived from gastric cancer promotes peritoneal metastasis via mesothelial-to-mesenchymal transition. Cell Death Dis 9:854. https:\/\/doi.org\/10.1038\/s41419-018-0928-8","journal-title":"Cell Death Dis"},{"key":"4011_CR124","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2147\/JAA.S307165","volume":"14","author":"X Li","year":"2021","unstructured":"Li X, Yang N, Cheng Q et al (2021) MiR-21-5p in macrophage-derived exosomes targets Smad7 to promote epithelial mesenchymal transition of airway epithelial cells. J Asthma Allergy 14:513\u2013524. https:\/\/doi.org\/10.2147\/JAA.S307165","journal-title":"J Asthma Allergy"},{"key":"4011_CR125","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41419-021-03803-8","volume":"12","author":"Q He","year":"2021","unstructured":"He Q, Ye A, Ye W et al (2021) Cancer-secreted exosomal miR-21-5p induces angiogenesis and vascular permeability by targeting KRIT1. Cell Death Dis 12:576. https:\/\/doi.org\/10.1038\/s41419-021-03803-8","journal-title":"Cell Death Dis"},{"key":"4011_CR126","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/diagnostics12061413","volume":"12","author":"J Dohmen","year":"2022","unstructured":"Dohmen J, Semaan A, Kobilay M et al (2022) Diagnostic potential of exosomal microRNAs in colorectal cancer. Diagnostics 12:1413. https:\/\/doi.org\/10.3390\/diagnostics12061413","journal-title":"Diagnostics"},{"key":"4011_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.643525","volume":"9","author":"J Li","year":"2021","unstructured":"Li J, Huang L, He Z et al (2021) Andrographolide suppresses the growth and metastasis of luminal-like breast cancer by inhibiting the NF-\u03baB\/miR-21-5p\/PDCD4 signaling pathway. Front Cell Dev Biol 9:643525. https:\/\/doi.org\/10.3389\/fcell.2021.643525","journal-title":"Front Cell Dev Biol"},{"key":"4011_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.116","volume":"6","author":"DC Schmitt","year":"2015","unstructured":"Schmitt DC, Madeira da Silva L, Zhang W et al (2015) ErbB2-intronic microRNA-4728: a novel tumor suppressor and antagonist of oncogenic MAPK signaling. Cell Death Dis 6:e1742. https:\/\/doi.org\/10.1038\/cddis.2015.116","journal-title":"Cell Death Dis"},{"key":"4011_CR129","doi-asserted-by":"publisher","first-page":"818493","DOI":"10.3389\/fmolb.2022.818493","volume":"9","author":"T Rui","year":"2022","unstructured":"Rui T, Xiang A, Guo J et al (2022) Mir-4728 is a valuable biomarker for diagnostic and prognostic assessment of HER2-positive breast cancer. Front Mol Biosci 9:818493. https:\/\/doi.org\/10.3389\/fmolb.2022.818493","journal-title":"Front Mol Biosci"},{"key":"4011_CR130","doi-asserted-by":"publisher","first-page":"E2594","DOI":"10.1073\/pnas.1717820115","volume":"115","author":"KV Floros","year":"2018","unstructured":"Floros KV, Lochmann TL, Hu B et al (2018) Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. Proc Natl Acad Sci U S A 115:E2594\u2013E2603. https:\/\/doi.org\/10.1073\/pnas.1717820115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4011_CR131","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245832","volume":"16","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Yuan Y, Li L et al (2021) HER2-intronic miR-4728-5p facilitates HER2 expression and accelerates cell proliferation and migration by targeting EBP1 in breast cancer. PLoS ONE 16:e0245832. https:\/\/doi.org\/10.1371\/journal.pone.0245832","journal-title":"PLoS ONE"},{"key":"4011_CR132","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.3390\/cancers14112585","volume":"14","author":"KY Du","year":"2022","unstructured":"Du KY, Qadir J, Yang BB et al (2022) Tracking miR-17-5p levels following expression of seven reported target mRNAs. Cancers 14:2585. https:\/\/doi.org\/10.3390\/cancers14112585","journal-title":"Cancers"},{"key":"4011_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110246","volume":"128","author":"J Song","year":"2020","unstructured":"Song J, Liu Y, Wang T et al (2020) MiR-17-5p promotes cellular proliferation and invasiveness by targeting RUNX3 in gastric cancer. Biomed Pharmacother 128:110246. https:\/\/doi.org\/10.1016\/j.biopha.2020.110246","journal-title":"Biomed Pharmacother"},{"key":"4011_CR134","doi-asserted-by":"publisher","first-page":"27214","DOI":"10.18632\/oncotarget.4877","volume":"6","author":"S Dhar","year":"2015","unstructured":"Dhar S, Kumar A, Rimando AM et al (2015) Resveratrol and pterostilbene epigenetically restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer. Oncotarget 6:27214\u201327226","journal-title":"Oncotarget"},{"key":"4011_CR135","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194638","volume":"13","author":"G Luengo-Gil","year":"2018","unstructured":"Luengo-Gil G, Gonzalez-Billalabeitia E, Perez-Henarejos SA et al (2018) Angiogenic role of miR-20a in breast cancer. PLoS ONE 13:e0194638. https:\/\/doi.org\/10.1371\/journal.pone.0194638","journal-title":"PLoS ONE"},{"key":"4011_CR136","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3892\/etm.2020.8432","volume":"19","author":"Z Xiao","year":"2020","unstructured":"Xiao Z, Chen S, Feng S et al (2020) Function and mechanisms of microRNA-20a in colorectal cancer. Exp Ther Med 19:1605\u20131616. https:\/\/doi.org\/10.3892\/etm.2020.8432","journal-title":"Exp Ther Med"},{"key":"4011_CR137","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3390\/bioengineering10080892","volume":"10","author":"M Daneshpour","year":"2023","unstructured":"Daneshpour M, Ghadimi-Daresajini A (2023) Overview of miR-106a regulatory roles: from cancer to aging. Bioengineering 10:892. https:\/\/doi.org\/10.3390\/bioengineering10080892","journal-title":"Bioengineering"},{"key":"4011_CR138","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1002\/cam4.863","volume":"5","author":"C Chen","year":"2016","unstructured":"Chen C, Lu Z, Yang J et al (2016) MiR-17-5p promotes cancer cell proliferation and tumorigenesis in nasopharyngeal carcinoma by targeting p21. Cancer Med 5:3489\u20133499. https:\/\/doi.org\/10.1002\/cam4.863","journal-title":"Cancer Med"},{"key":"4011_CR139","first-page":"3827","volume":"8","author":"X Xie","year":"2015","unstructured":"Xie X, Liu H-T, Mei J et al (2015) miR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN. Int J Clin Exp Pathol 8:3827\u20133834","journal-title":"Int J Clin Exp Pathol"},{"key":"4011_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154789","volume":"250","author":"H Moutabian","year":"2023","unstructured":"Moutabian H, Radi UK, Saleman AY et al (2023) MicroRNA-155 and cancer metastasis: regulation of invasion, migration, and epithelial-to-mesenchymal transition. Pathol Res Pract 250:154789. https:\/\/doi.org\/10.1016\/j.prp.2023.154789","journal-title":"Pathol Res Pract"},{"key":"4011_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116412","volume":"174","author":"M Shen","year":"2024","unstructured":"Shen M, Chen T, Li X et al (2024) The role of miR-155 in urologic malignancies. Biomed Pharmacother 174:116412. https:\/\/doi.org\/10.1016\/j.biopha.2024.116412","journal-title":"Biomed Pharmacother"},{"key":"4011_CR142","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2217\/bmm-2018-0127","volume":"13","author":"Z Nariman-Saleh-Fam","year":"2019","unstructured":"Nariman-Saleh-Fam Z, Saadatian Z, Daraei A et al (2019) The intricate role of miR-155 in carcinogenesis: potential implications for esophageal cancer research. Biomark Med 13:147\u2013159. https:\/\/doi.org\/10.2217\/bmm-2018-0127","journal-title":"Biomark Med"},{"key":"4011_CR143","doi-asserted-by":"publisher","first-page":"29224","DOI":"10.18632\/oncotarget.4942","volume":"6","author":"KG Thomsen","year":"2015","unstructured":"Thomsen KG, Terp MG, Lund RR et al (2015) miR-155, identified as anti-metastatic by global miRNA profiling of a metastasis model, inhibits cancer cell extravasation and colonization in vivo and causes significant signaling alterations. Oncotarget 6:29224\u201329239","journal-title":"Oncotarget"},{"key":"4011_CR144","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020687","volume":"6","author":"JJ LaConti","year":"2011","unstructured":"LaConti JJ, Shivapurkar N, Preet A et al (2011) Tissue and serum microRNAs in the KrasG12D transgenic animal model and in patients with pancreatic cancer. PLoS ONE 6:e20687. https:\/\/doi.org\/10.1371\/journal.pone.0020687","journal-title":"PLoS ONE"},{"key":"4011_CR145","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/cbin.11530","volume":"45","author":"N Dastmalchi","year":"2021","unstructured":"Dastmalchi N, Baradaran B, Banan Khojasteh SM et al (2021) miR-424: a novel potential therapeutic target and prognostic factor in malignancies. Cell Biol Int 45:720\u2013730. https:\/\/doi.org\/10.1002\/cbin.11530","journal-title":"Cell Biol Int"},{"key":"4011_CR146","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12094-023-03209-2","volume":"26","author":"S Ghafouri-Fard","year":"2024","unstructured":"Ghafouri-Fard S, Askari A, Hussen BM et al (2024) Role of miR-424 in the carcinogenesis. Clin Transl Oncol 26:16\u201338. https:\/\/doi.org\/10.1007\/s12094-023-03209-2","journal-title":"Clin Transl Oncol"},{"key":"4011_CR147","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.3390\/molecules26092506","volume":"26","author":"WH Talib","year":"2021","unstructured":"Talib WH, Alsayed AR, Abuawad A et al (2021) Melatonin in cancer treatment: current knowledge and future opportunities. Molecules 26:2506. https:\/\/doi.org\/10.3390\/molecules26092506","journal-title":"Molecules"},{"key":"4011_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.926895","volume":"13","author":"S Ghafouri-Fard","year":"2022","unstructured":"Ghafouri-Fard S, Shoorei H, Poornajaf Y et al (2022) NLRP3: Role in ischemia\/reperfusion injuries. Front Immunol 13:926895. https:\/\/doi.org\/10.3389\/fimmu.2022.926895","journal-title":"Front Immunol"},{"key":"4011_CR149","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1101\/gad.292318.116","volume":"31","author":"R Rodriguez-Barrueco","year":"2017","unstructured":"Rodriguez-Barrueco R, Nekritz EA, Bertucci F et al (2017) miR-424(322)\/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes Dev 31:553\u2013566. https:\/\/doi.org\/10.1101\/gad.292318.116","journal-title":"Genes Dev"},{"key":"4011_CR150","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-16-2541","volume":"23","author":"W Weng","year":"2017","unstructured":"Weng W, Wei Q, Toden S et al (2017) Circular RNA ciRS-7\u2014A promising prognostic biomarker and a potential therapeutic target in colorectal cancer. Clin Cancer Res 23:3918\u20133928. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2541","journal-title":"Clin Cancer Res"},{"key":"4011_CR151","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/0008-5472.CAN-22-2213","volume":"83","author":"J Zhuang","year":"2023","unstructured":"Zhuang J, Shen L, Li M et al (2023) Cancer-associated fibroblast-derived miR-146a-5p generates a niche that promotes bladder cancer stemness and chemoresistance. Cancer Res 83:1611\u20131627. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-2213","journal-title":"Cancer Res"},{"key":"4011_CR152","doi-asserted-by":"publisher","first-page":"20741","DOI":"10.18632\/oncotarget.15119","volume":"8","author":"X Wu","year":"2017","unstructured":"Wu X, Tao P, Zhou Q et al (2017) IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2\/STAT3 signaling pathway. Oncotarget 8:20741\u201320750. https:\/\/doi.org\/10.18632\/oncotarget.15119","journal-title":"Oncotarget"},{"key":"4011_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-022-04825-6","volume":"13","author":"D Wang","year":"2022","unstructured":"Wang D, Wang X, Song Y et al (2022) Exosomal miR-146a-5p and miR-155-5p promote CXCL12\/CXCR7-induced metastasis of colorectal cancer by crosstalk with cancer-associated fibroblasts. Cell Death Dis 13:1\u201315. https:\/\/doi.org\/10.1038\/s41419-022-04825-6","journal-title":"Cell Death Dis"},{"key":"4011_CR154","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.canlet.2014.05.013","volume":"351","author":"S Ali","year":"2014","unstructured":"Ali S, Ahmad A, Aboukameel A et al (2014) Deregulation of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling. Cancer Lett 351:134\u2013142. https:\/\/doi.org\/10.1016\/j.canlet.2014.05.013","journal-title":"Cancer Lett"},{"key":"4011_CR155","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/pros.22466","volume":"72","author":"B Xu","year":"2012","unstructured":"Xu B, Wang N, Wang X et al (2012) MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate 72:1171\u20131178. https:\/\/doi.org\/10.1002\/pros.22466","journal-title":"Prostate"},{"key":"4011_CR156","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1261\/rna.874808","volume":"14","author":"S-L Lin","year":"2008","unstructured":"Lin S-L, Chiang A, Chang D, Ying S-Y (2008) Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14:417\u2013424. https:\/\/doi.org\/10.1261\/rna.874808","journal-title":"RNA"},{"key":"4011_CR157","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1084\/jem.20101823","volume":"208","author":"MP Boldin","year":"2011","unstructured":"Boldin MP, Taganov KD, Rao DS et al (2011) miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 208:1189\u20131201. https:\/\/doi.org\/10.1084\/jem.20101823","journal-title":"J Exp Med"},{"key":"4011_CR158","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.3390\/cells11182791","volume":"11","author":"J Rhim","year":"2022","unstructured":"Rhim J, Baek W, Seo Y, Kim JH (2022) From molecular mechanisms to therapeutics: understanding microRNA-21 in cancer. Cells 11:2791. https:\/\/doi.org\/10.3390\/cells11182791","journal-title":"Cells"},{"key":"4011_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155091","volume":"254","author":"HS Chawra","year":"2024","unstructured":"Chawra HS, Agarwal M, Mishra A et al (2024) MicroRNA-21\u2019s role in PTEN suppression and PI3K\/AKT activation: implications for cancer biology. Pathol Res Pract 254:155091. https:\/\/doi.org\/10.1016\/j.prp.2024.155091","journal-title":"Pathol Res Pract"},{"key":"4011_CR160","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.omtn.2020.03.003","volume":"20","author":"D Bautista-S\u00e1nchez","year":"2020","unstructured":"Bautista-S\u00e1nchez D, Arriaga-Canon C, Pedroza-Torres A et al (2020) The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics. Mol Ther Nucleic Acids 20:409\u2013420. https:\/\/doi.org\/10.1016\/j.omtn.2020.03.003","journal-title":"Mol Ther Nucleic Acids"},{"key":"4011_CR161","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.1158\/0008-5472.CAN-09-1448","volume":"69","author":"J Ribas","year":"2009","unstructured":"Ribas J, Ni X, Haffner M et al (2009) miR-21: an androgen receptor regulated microRNA which promotes hormone dependent and independent prostate cancer growth. Cancer Res 69:7165\u20137169. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1448","journal-title":"Cancer Res"},{"key":"4011_CR162","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.642030","volume":"11","author":"Y Hong","year":"2021","unstructured":"Hong Y, Ye M, Wang F et al (2021) MiR-21-3p promotes hepatocellular carcinoma progression via SMAD7\/YAP1 regulation. Front Oncol 11:642030. https:\/\/doi.org\/10.3389\/fonc.2021.642030","journal-title":"Front Oncol"},{"key":"4011_CR163","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.1172\/JCI127125","volume":"129","author":"M Sahraei","year":"2019","unstructured":"Sahraei M, Chaube B, Liu Y et al (2019) Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response. J Clin Invest 129:5518\u20135536. https:\/\/doi.org\/10.1172\/JCI127125","journal-title":"J Clin Invest"},{"key":"4011_CR164","first-page":"21","volume":"49","author":"X Wu","year":"2020","unstructured":"Wu X (2020) Expressions of miR-21 and miR-210 in breast cancer and their predictive values for prognosis. Iran J Public Health 49:21\u201329","journal-title":"Iran J Public Health"},{"key":"4011_CR165","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071472","volume":"8","author":"D Zhao","year":"2013","unstructured":"Zhao D, Tu Y, Wan L et al (2013) In Vivo monitoring of angiogenesis inhibition via down-regulation of Mir-21 in a VEGFR2-Luc murine breast cancer model using bioluminescent imaging. PLoS ONE 8:e71472. https:\/\/doi.org\/10.1371\/journal.pone.0071472","journal-title":"PLoS ONE"},{"key":"4011_CR166","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/cancers4040420","volume":"4","author":"E Thara","year":"2012","unstructured":"Thara E, Dorff TB, Averia-Suboc M et al (2012) Immune response to sipuleucel-T in prostate cancer. Cancers 4:420\u2013441. https:\/\/doi.org\/10.3390\/cancers4040420","journal-title":"Cancers"},{"key":"4011_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","volume":"18","author":"PK Bommareddy","year":"2017","unstructured":"Bommareddy PK, Patel A, Hossain S, Kaufman HL (2017) Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am J Clin Dermatol 18:1\u201315. https:\/\/doi.org\/10.1007\/s40257-016-0238-9","journal-title":"Am J Clin Dermatol"},{"key":"4011_CR168","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2217\/1750743X.1.2.281","volume":"1","author":"TP Kresowik","year":"2009","unstructured":"Kresowik TP, Griffith TS (2009) Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy 1:281\u2013288. https:\/\/doi.org\/10.2217\/1750743X.1.2.281","journal-title":"Immunotherapy"},{"key":"4011_CR169","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","volume":"26","author":"AA Wu","year":"2020","unstructured":"Wu AA, Bever KM, Ho WJ et al (2020) A phase 2 study of allogeneic GM-CSF transfected pancreatic tumor vaccine (GVAX) with ipilimumab as maintenance treatment for metastatic pancreatic cancer. Clin Cancer Res Offic J Am Assoc Cancer Res 26:5129. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1025","journal-title":"Clin Cancer Res Offic J Am Assoc Cancer Res"},{"key":"4011_CR170","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","volume":"14","author":"G Jf","year":"2024","unstructured":"Jf G, Mr P, Js W et al (2024) T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study. Cancer Discov 14:2209\u20132223. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0158","journal-title":"Cancer Discov"},{"key":"4011_CR171","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/cancers14010033","volume":"14","author":"JZ Zhou","year":"2021","unstructured":"Zhou JZ, Jou J, Cohen E (2021) Vaccine strategies for human papillomavirus-associated head and neck cancers. Cancers 14:33. https:\/\/doi.org\/10.3390\/cancers14010033","journal-title":"Cancers"},{"key":"4011_CR172","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","volume":"9","author":"R Thomas","year":"2018","unstructured":"Thomas R, Al-Khadairi G, Roelands J et al (2018) NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol 9:947. https:\/\/doi.org\/10.3389\/fimmu.2018.00947","journal-title":"Front Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04011-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04011-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04011-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T10:49:04Z","timestamp":1745750944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04011-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":172,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["4011"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04011-5","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The paper is submitted with the consent of all listed authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"163"}}